Special Issue: Resistance to Targeted Therapies in Human Cancer

Tae-Won Lee¹, Hee-Joo Choi^{2

3

4}, Kyung-Min Lee^{1

4

5

6}, Jeong-Yeon Lee^{2

4}

Affiliations

¹ Department of Life Science, College of Natural Sciences, Hanyang University, Seoul 04763, Republic of Korea.
² Department of Pathology, College of Medicine, Hanyang University, Seoul 04763, Republic of Korea.
³ Hanyang Biomedical Research Institute, Hanyang University, Seoul 04763, Republic of Korea.
⁴ Hanyang Institute of Bioscience and Biotechnology, Hanyang University, Seoul 04763, Republic of Korea.
⁵ Research Institute for Natural Sciences, Hanyang University, Seoul 04763, Republic of Korea.
⁶ Research Institute for Convergence of Basic Sciences, Hanyang University, Seoul 04763, Republic of Korea.

Editorial

Tae-Won Lee et al. Biomedicines. 2023.

. 2023 Jan 31;11(2):414.

doi: 10.3390/biomedicines11020414.

Tae-Won Lee¹, Hee-Joo Choi^{2

3

4}, Kyung-Min Lee^{1

4

5

6}, Jeong-Yeon Lee^{2

4}

¹ Department of Life Science, College of Natural Sciences, Hanyang University, Seoul 04763, Republic of Korea.
² Department of Pathology, College of Medicine, Hanyang University, Seoul 04763, Republic of Korea.
³ Hanyang Biomedical Research Institute, Hanyang University, Seoul 04763, Republic of Korea.
⁴ Hanyang Institute of Bioscience and Biotechnology, Hanyang University, Seoul 04763, Republic of Korea.
⁵ Research Institute for Natural Sciences, Hanyang University, Seoul 04763, Republic of Korea.
⁶ Research Institute for Convergence of Basic Sciences, Hanyang University, Seoul 04763, Republic of Korea.

Abstract

Cancer is the second leading cause of death worldwide, accounting for approximately 10 million deaths in 2020 [...].

The author declares no conflict of interest.

1. Montoya S., Soong D., Nguyen N., Affer M., Munamarty S.P., Taylor J. Targeted Therapies in Cancer: To Be or Not to Be, Selective. Biomedicines. 2021;9:1591. doi: 10.3390/biomedicines9111591. - DOI - PMC - PubMed
1. Juengel E., Schnalke P., Rutz J., Maxeiner S., Chun F.K., Blaheta R.A. Antiangiogenic Properties of Axitinib versus Sorafenib Following Sunitinib Resistance in Human Endothelial Cells-A View towards Second Line Renal Cell Carcinoma Treatment. Biomedicines. 2021;9:1630. doi: 10.3390/biomedicines9111630. - DOI - PMC - PubMed
1. Balkwill F.R., Capasso M., Hagemann T. The tumor microenvironment at a glance. J. Cell Sci. 2012;125:5591–5596. doi: 10.1242/jcs.116392. - DOI - PubMed
1. Mollah F., Varamini P. Overcoming Therapy Resistance and Relapse in TNBC: Emerging Technologies to Target Breast Cancer-Associated Fibroblasts. Biomedicines. 2021;9:1921. doi: 10.3390/biomedicines9121921. - DOI - PMC - PubMed
1. Binnewies M., Roberts E.W., Kersten K., Chan V., Fearon D.F., Merad M., Coussens L.M., Gabrilovich D.I., Ostrand-Rosenberg S., Hedrick C.C., et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat. Med. 2018;24:541–550. doi: 10.1038/s41591-018-0014-x. - DOI - PMC - PubMed